Reporter Glenn Greenwald, who has been in the news recently for disseminating the whistle-blower and former CIA employee Edward Snowden’s information on the US’s mass surveillance program has left The Guardian where his initial articles appeared
Reporter Glenn Greenwald, who has been in the news recently for disseminating the whistle-blower and former CIA employee Edward Snowden’s information on the US’s mass surveillance program has left The Guardian where his initial articles appeared. Along with filmmaker Laura Poitras (also covering the Snowden story) and Jeremy Scahill, Greenwald is joining up with Pierre Omidyar, one of the founders of Ebay, who has announced that he’s funding a journalism project with $250 million dollars in seed money.
It’s intriguing media news in a world where the line between editorial and advertising is increasingly blurred, and publications are dying off like flies.
Omidyar intends to publish progressive, long-form, investigative stories written by the country’s best specialist writers on a variey of different subjects.
Whose on his dream team? He published his wish list on Tuesday on Opednews.com.
And who would he pick to cover the pharma industry? Martha Rosenberg, he says, “who does great investigative reporting on food and drug safety and Big Pharma and Big Agra.”
Her work is certainly provocative and hardhitting, and sometimes loads of fun to read, but is it fair?
Writing for a variey of publications, here are just a few of her recent titles:
6 New Ways Big Pharma Is Scheming to Make Billions at the Expense of Your Health
Big Pharma Company Mocked Patients Who Got “Jawbone Death” from Drug
How Kids Are Getting Hooked on Pills for Life
You get the idea. My personal point of view is that it’s easy to muckrake, but a lot harder to dig deep to reveal texture and complexity of a topic. But we will wait and see. There’s always room for other voices.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.